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Abstract 
 
Transforming growth factor- (TGF-) superfamily members signal via membrane-bound 
heteromeric serine-threonine kinase receptor complexes. Upon ligand binding, receptor 
activation leads to phosphorylation of cytoplasmic protein substrates of the Smad family. 
Following phosphorylation and oligomerization, the latter move into the nucleus to act as 
transcription factors to regulate target gene expression. TGF- responses are not solely the 
result of the activation Smad cascade, but are highly cell-type specific and dependent upon 
interactions of Smad signaling with a variety of other intracellular signaling mechanisms, 
initiated or not by TGF- itself, that may either potentiate, synergize, or antagonize, the rather 
linear TGF-/Smad pathway. These include, (a), regulation of Smad activity by mitogen-
activated protein kinases (MAPKs), (b), nuclear interaction of activated Smads with 
transcriptional cofactors, whether co-activators or co-repressors, that may be themselves be 
regulated by diverse signaling mechanisms, and (c), negative feedback loops exerted by 
inhibitory Smads, transcriptional targets of the Smad cascade. This review focuses on how 
MAPKs modulate the outcome of Smad activation by TGF-, and how cross signaling 
mechanisms between the Smad and MAPK pathways may take place and affect cell fate in 
the context of carcinogenesis. 
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Introduction 
 
Members of the TGF- superfamily (TGF-s, activins, bone morphogenic proteins/BMPs) 
signal via heteromeric serine/threonine kinase transmembrane receptor complexes (Derynck 
& Feng, 1997; Javelaud & Mauviel, 2004; ten Dijke & Hill, 2004). Binding of the ligand to 
its primary (type II) receptor, a constitutively active kinase, allows the recruitment, 
transphosphorylation and activation of the signaling (type I) receptor. The latter is then able to 
exert its phosphorylation-dependent serine-threonine kinase activity to phosphorylate 
cytoplasmic protein mediators of the Smad family (Derynck et al., 1998; Miyazono et al., 
2000; Shi & Massague, 2003). The ligand-specific, receptor-activated Smads (R-Smads), 
Smad1, Smad2, Smad3, Smad5 and Smad8, interact directly with, and are phosphorylated by, 
activated TGF- receptors type I (Zimmerman & Padgett, 2000). Smads 1,5,8 are specific 
substrates of the BMP receptors, whereas Smad2 and Smad3 are activated by both TGF- and 
activin receptors. R-Smads consist of two conserved Mad-homology (MH) domains that form 
globular structures separated by a linker region (Hill, 1999; Miyazono et al., 2000; Shi & 
Massague, 2003). The N-terminal MH1 domain has DNA-binding activity whereas the C-
terminal MH2 domain has protein-binding properties. Phosphorylation of R-Smads by type I 
receptors occurs principally on two serine residues within a conserved -SS(M/V)S- motif at 
their C-terminus. Upon phosphorylation, they form heteromeric complexes with Smad4, a 
common mediator for all Smad pathways. The resulting Smad heterocomplexes are then 
translocated into the nucleus where they activate target genes, binding DNA either directly or 
in association with other transcription factors (Derynck & Feng, 1997; Hill, 1999; Javelaud & 
Mauviel, 2004; Miyazono et al., 2000; Shi & Massague, 2003; ten Dijke & Hill, 2004). 
Members of the third group of Smads, known as inhibitory Smads Smad6 and Smad7, control 
Smad signaling by preventing phosphorylation and/or nuclear translocation of receptor-
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associated Smads and by inducing receptor complex degradation through the recruitment of 
ubiquitin-ligases that induce proteasomal degradation (Ebisawa et al., 2001; Hayashi et al., 
1997; Kavsak et al., 2000; Zhang et al., 2001). More recently, Smad7 was also shown to 
recruit and stabilize the protein phosphatase PP1/GADD34 complex to the activated TGF- 
receptors, thereby inducing receptor dephosphorylation and de-activation (Shi et al., 2004). 
Following target gene transcription, Smad complexes are released from the chromatin and 
may undergo ubiquitination followed by proteasomal degradation (reviewed in (Wang, 
2003)), or may shuttle out of the nucleus for de novo phosphorylation by activated TGF- 
receptors and re-entry into the nucleus for further gene regulatory functions (Di Guglielmo et 
al., 2003; Nicolas et al., 2004; Penheiter et al., 2002; Xiao et al., 2001).  
The Smad pathway may not be viewed at a unique mean for TGF-s to regulate cellular 
functions, as other signaling pathways including the mitogen-activated protein kinase 
(MAPK), the NF-B or PI3 kinase/AKT pathways, can either be induced by TGF-, or can 
modulate the outcome of TGF--induced Smad signaling (Derynck & Zhang, 2003; Lutz & 
Knaus, 2002; Massagué & Chen, 2000). Indeed, broad evidence exists for a tight integration 
of Smad signaling within a complex network of crosstalks with other signaling pathways that 
largely contribute to modify the initial Smad signals and allow the pleiotropic activities of 
TGF-. Also, there may be instances whereby Smad signaling may even be dispensable for 
some of TGF- responses, as exemplified by Smad-independent activation of the cyclin 
kinase inhibitors p15 and p21 in HaCaT keratinocytes (Hu et al., 1999), or transcriptional 
activation of the fibronectin promoter via MAPK-dependent mechanisms (Hocevar et al., 
1999). 
Interestingly, it appears now clearly that Smad proteins are not only the primary substrates for 
the TGF- receptor kinases, but may also be phosphorylated by MAPKs, in response to either 
TGF- itself or to various cytokines. Such R-Smad phosphorylation by MAPKs may serve to 
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regulate either Smad transcriptional activity or capacity to translocate into the cell nucleus 
(Derynck & Zhang, 2003; Lutz & Knaus, 2002; Massagué & Chen, 2000). Also, Smad 
proteins are also capable of physically interacting with transcription factors, themselves 
substrates of MAPKs, adding more complexity to the intricate relationship between MAPKs 
and the Smad pathway. 
This review will summarize some of the latest data from the literature regarding MAPK and 
Smad interactions, with a main focus on the cellular events contributing to the various stages 
of carcinogenesis.  
 
The MAPK signaling cascades and substrates 
  
MAP kinases are a large group of proteins that allow numerous extracellular signals reaching 
the cell surface to rapidly activate nuclear transcription factors (Whitmarsh & Davis, 1999). 
They mainly consist in three subfamilies: the extracellular signal-regulated kinases (ERK1 
and ERK2), the stress-activated protein (SAP) kinases known as c-Jun N-terminal kinase 
(JNK1, JNK2 and JNK3), and the p38/MAPKs (, ,  and ) (Chang & Karin, 2001). ERK5, 
described as a mediator of Src activation (Zhou et al., 1995), is another member of the MAP 
kinase superfamily but thus far, unlike the first three groups of MAKs, it has not been shown 
to be activated by TGF-, or to interfere with Smad signaling. 
 
Signaling initiated by each MAPK pathway occurs through sequential activation of a MAPK 
kinase kinase (MAPKKK) by membrane-associated kinases such as cytokine or growth factor 
receptors, a MAPK kinase (MAPKK), leading to phospho-activation of an MAPK (Lowes et 
al., 2002). MAPK activation leads to downstream phosphorylation of nuclear kinases or, most 
commonly, transcription factors. A simplified view of the various MAPK pathways is 
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provided in Fig. 1, which refers to most MAPK members and substrates cited in the text 
below. 
ERKs are phosphorylated by the MAPKKs MEK1 and MEK2, themselves substrates of the 
MAPKKK Raf-1, the latter being activated by the membrane-bound small G-protein Ras, for 
example following induction by mitogenic stimuli such as epidermal growth factor (EGF) 
upon binding and activation of their receptors. JNK family members are the substrates of 
MKK4 (also known as SEK1) and MKK7. p38/MAPK is phosphorylated by MKK3 and 
MKK6, themselves the substrates of several MAPKKKs, including, but not restricted to, 
apoptosis signal-regulating kinase-1 (ASK1), mixed lineage kinases (MLKs), and TGF--
activated kinase-1 (TAK1) (Davis, 2000; Ip & Davis, 1998). ERK-mediated pathways are 
mostly involved in proliferation and differentiation and generally considered anti-apoptotic. 
JNK and p38 signaling pathways are activated by stress stimuli, many of which induce 
apoptosis, but in some cellular systems they have been implicated in proliferation and 
differentiation as well (Eferl & Wagner, 2003). 
A variety of transcription factors, and some downstream kinases, serve as substrates for 
activated MAPKs (Treisman, 1996). Among them is activating protein-1 (AP-1), a family of 
pleiotropic transcription factors comprised of homo- and heterodimers of Fos, Jun and ATF 
family members, involved in the control of cell proliferation, death and survival, as well as 
tumorigenesis (Eferl & Wagner, 2003; Karin et al., 1997; Shaulian & Karin, 2001; Shaulian & 
Karin, 2002). ERK1/2 phosphorylate TCF/Elk-1, and activate CREB and c-Fos through the 
MSK1 and RSK kinases, respectively. p38 MAPKs activate Elk-1, CHOP, ATF-2, CREB and 
MEF2C (Hazzalin & Mahadevan, 2002). JNK is the only MAPK to phosphorylate c-Jun, the 
main component of AP-1 complexes, and also has ATF-2 and Elk-1 as substrate (Chang & 
Karin, 2001). Phosphorylation of c-Jun results in the activation of this key member of the AP-
1 family of transcription factors, which can then bind specific AP-1 recognition sites 
 7 
TGAG/CTCA, to transactivate target genes (Angel & Karin, 1991). Upon activation, CREB 
and ATF-2 bind to CRE sites (TGACGTCA) on target gene promoters (Smeal et al., 1994). 
Heterodimers of c-Jun and ATF-2 have also been shown to bind to CRE sites (Hai & Curran, 
1991).  
 
Activation of MAPKs by TGF-
 
Many TGF--regulated gene promoters, including the TGF-1 promoter, contain either AP-1- 
or CRE binding sites (Chung et al., 1996; Mauviel et al., 1993; Roberts et al., 1991; Wong et 
al., 1999). Complex interactions between the Ras pathway and TGF- signaling exist at 
various stages of carcinogenesis, suggesting interference of signaling pathways (Akhurst & 
Derynck, 2001). Also, a MAPKKK homolog activated by TGF-, TAK1, was identified in 
the mid 90s, a direct indication that TGF- may indeed activate the MAPK kinase pathways 
(Yamaguchi et al., 1995). Of note, MAPK activation is, not a specific feature of TGF- 
signaling and may be the result of various extracellular stimuli, including cytokines, 
ultraviolet irradiation, cell-cell or cell-matrix contacts, to cite a few. The outcome of Smad-
MAPK interactions should therefore not be viewed solely as the result of multi-facetted TGF-
 signaling downstream of its receptors, but also as a consequence of cytokine networks 
acting in concert to modulate Smad/MAPK signals. 
TGF- has been shown in numerous cell types to activate all ERK, p38 and JNK MAPKs 
(reviewed in (Derynck & Zhang, 2003; Wakefield & Roberts, 2002)). Not only is MAPK 
activation by TGF- cell-type specific, but the activation of a given MAPK combination by 
TGF- is also cell-type dependent. For example, in mink lung epithelial cells, TGF--induced 
activation of JNK mediates Smad3 phosphorylation, which is required for the transcriptional 
activation of Smad3-dependent responses (Engel et al., 1999). On the other hand, in rat 
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articular chondrocytes, TGF- induces a rapid activation of ERK1/2, but not that of either p38 
or JNK MAPKs (Yonekura et al., 1999). Multiple other examples have been described in the 
literature. 
 
Activation of MAPKs by TGF- has been described to occur either with slow kinetics, 
possibly resulting from Smad-dependent transcription responses, but also with rapid kinetics 
similar to those observed downstream of cytokine receptors. In the latter case, the rapid 
activation (5–15 min) of MAPK phosphorylation strongly not only suggests independence 
from Smad-driven transcription but also direct activation of MAPKKKs. 
Initial evidence for Smad-independent activation of MAPK by TGF- was obtained in 
Smad4-deficient cells, or in cells overexpressing dominant-negative Smads, where activation 
of the JNK/MAPK pathway was still possible in response to TGF- despite the deficient 
Smad cascade (Itoh et al., 2002). Also, it has been shown that mutated TGF- type I 
receptors, that can not phosphorylates R-Smad still activate p38 MAPK signaling in response 
to TGF- (Yu et al., 2002). The mechanisms of Erk, JNK or p38 MAPK activation by TGF- 
and its biological consequences are not fully characterized. ERK activation by TGF- in 
epithelial cells may implicate Ras signaling (Yue & Mulder, 2000), while JNK and p38 
MAPK signaling could be activated by various MAPKKKs in response to many stimuli. The 
first known MAPKKK to be activated by TGF- family members is TGF--activated kinase 1 
(TAK1), originally identified as a MAPKKK activated by TAB1 (for TGF--activated kinase 
binding protein-1) downstream of TGF-/BMP receptors, positively regulating the 
SAPK/JNK and p38 kinase pathways (Yamaguchi et al., 1995). TAB1 is able to associate 
with the inhibitory Smad, Smad7, a phenomenon that may lead to inhibition of TAK-1-
dependent p38 activation (Edlund et al., 2003). Alternatively, it has also been suggested that 
Smad7 could act as a scaffolding protein to provide structural support for MKK3/p38 
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activation by TAK1. Of note, because TAK1 also activates NF-B, TGF-/BMP receptors, 
due to their ability to activate TAK1, may, under certain circumstances, also induce NF-B 
signaling (Arsura et al., 2003). XIAP (X-linked inhibitor of apoptosis), was then identified as 
a bridging molecule between TGF-/BMP receptors and TAK-1/TAB-1, serving as a co-
factor for TAK-1-dependent signaling (Yamaguchi et al., 1999). Uncertainty remains 
however, as (a), some of the cooperative activities of XIAP and TGF- are not mediated by 
TAK-1-dependent signals, and (b), XIAP may also be dispensable for TGF- signaling. For 
example, activation of TGF- responsive genes by XIAP has been shown to depend on 
Smad4, while the anti-apoptotic effects of XIAP are Smad4-independent (Birkey Reffey et 
al., 2001). Furthermore, XIAP-deficient mice respond to TGF- (Harlin et al., 2001). This 
could be explained if a direct link between TAK1 (in association with the cofactor TAB1) and 
the receptors is established by another upstream kinase, such as the hematopoietic progenitor 
kinase-1 (HPK1), which allows JNK activation by bridging the TGF- receptors to TAK1 
independently from XIAP (Zhou et al., 1999). 
MEKK1 may also function upstream of TGF--mediated activation of MAPKKs (Brown et 
al., 1999); thus, MEKK1 and TAK1 could activate JNK through MAPK kinase 4 (MKK4), 
and p38 MAPK through MKK3 or MKK6, in response to TGF-.  
In a yeast two-hybrid screen designed to identify proteins interacting with the cytoplasmic tail 
of the TGF- type II receptor, Daxx, a protein capable of blocking TGF- induced apoptosis 
in B-cell lymphomas, and involved in the activation of the JNK pathway by TGF-, was 
isolated (Perlman et al., 2001). Daxx was previously known as an adaptor protein for the Fas 
receptor, that mediates Fas activation of Jun amino-terminal kinase (JNK) and programmed 
cell death (Yang et al., 1997). Daxx thus appears to also function as an adaptor protein linking 
the TGF- receptor complex to the apoptotic machinery and the JNK pathway. 
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TGF-1 may induce both a rapid and a late activation of p38 depending on the cell type. 
Rapid, transient, p38 activation has been described in certain cell types including human 
neutrophils, HEK293, and C2C12 cells, and may be mediated by the induction of TAK1 in a 
R-Smad-independent manner. On the other hand, the delayed and sustained p38 activation 
observed in pancreatic carcinoma cells, hepatocytes, or osteoblasts, requires Smad signaling: 
Smad activation results in the induction of the expression of Gadd45b, an upstream activator 
of MKK4, which thus promotes the delayed activation of p38 MAPK (Takekawa et al., 2002). 
Likewise, JNK activation may occur rapidly or in a delayed manner (Engel et al., 1998), and 
among potential candidates that could mediate a delayed JNK activation following TGF- 
treatment, is the inhibitory Smad, Smad7, a TGF-/Smad target whose overexpression has 
been shown to induce persistent JNK activation in HepG2 cells (Mazars et al., 2001). At 
present, the exact mechanism(s) by which Smad7 activates the JNK pathway remains elusive. 
Depending on the cell line, TGF- can rapidly activate the Rho-like GTPases, RhoA, RhoB, 
Rac and Cdc. Ras activation in response to TGF- may also lead to activation of Rho-like 
GTPases. (Atfi et al., 1997; Edlund et al., 2002; Kamaraju & Roberts, 2005; Mucsi et al., 
1996). Rac and Cdc42 regulate JNK and p38 MAPK pathway activation, presumably by 
directly interacting with MAPKKKs upstream of JNK and p38 MAPK.  
 
Modulation of Smad activity by MAPKs 
 
MAP kinases can modify Smad signaling by phosphorylation-dependent modification of 
ligand-dependent R-Smad nuclear translocation. Thus, Ras signaling has been proposed to 
inhibit TGF- signaling via the ERK pathway. Specifically, ERK has been shown to 
phosphorylate the linker region of Smad1, Smad2 and Smad3, which results in blocking the 
nuclear translocation of these TGF--activated Smads (Kretzschmar et al., 1999). It was 
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proposed that such mechanism might explain why some cells with hyperactive Ras signaling 
do not respond to TGF- (Calonge & Massagué, 1999; Kretzschmar et al., 1999). However, 
other reports have demonstrated impaired nuclear translocation of Smads in Ras-transformed 
cells or in cells with activated MAP kinase signaling, despite efficient phosphorylation of R-
Smad linker regions by ERK (Engel et al., 1999). Furthermore, cooperativity between 
Ras/MAP kinase signaling and TGF- signaling has been observed during tumor cell 
differentiation and behavior (Lehmann et al., 2000; Oft et al., 1996), not compatible with the 
hypothesis of a blocade of TGF- signaling by Ras.  
The issue of whether MAPK phosphorylation of Smads impairs or not their nuclear 
translocation is very complex: ERK activation, while all potential ERK or JNK sites in the 
middle-linker regions of Smad2 are mutated, is associated with phosphorylation of the R-
Smad outside the C-terminal –SSMS motif and leads to enhanced nuclear translocation of 
Smad2 (Brown et al., 1999; de Caestecker et al., 1998). Furthermore, TGF--dependent 
phosphorylation sites in Smad2 overlap with the Smad2 phosphopeptide maps seen following 
activation of the ERK1/2 MAP kinase pathway by HGF (de Caestecker et al., 1998), 
suggesting that common sites of MAP kinase-induced phosphorylation may also be required 
for TGF--dependent nuclear translocation of the R-Smad/Smad4 complex.  
ERKs are not the only MAPKs capable of phosphorylating Smads. Work by Matsuzaki’s 
group showed JNK-dependent phosphorylation of Smad2 and Smad3 in response to HGF, 
PDGF and TGF- itself, with no loss of R-Smad capacity to translocate into the nucleus or to 
transactivate target genes (Mori et al., 2004; Yoshida et al., 2005).  
Recently, it was shown that the human breast cancer cell line MCF10CA1h that the 
Rho/ROCK and p38 pathways cooperate to allow TGF--induced growth arrest (Kamaraju & 
Roberts, 2005). This effect is achieved by phosphorylation of the R-Smad linker regions by 
both kinases, resulting in an increased transactivation potential of R-Smads, ultimately 
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leading to cell cycle withdrawal. 
MAPKs may indirectly affect Smad signaling by controlling Smad7 expression. Initial 
observations by Brodin et al. indicated that TGF--induced Smad7 expression depends on 
cooperative interactions between AP-1, Sp1 and Smad proteins (Brodin et al., 2000). More 
recently, both the JNK and TAK1/p38 pathways were shown to regulate Smad7 expression, in 
a cell-type specific manner (Dowdy et al., 2003; Uchida et al., 2001). Also, ultraviolet 
irradiation, a know activator of MAPKs, activates Smad7 transcription in a c-Jun-dependent 
manner (Quan et al., 2005). 
Finally, MAPKs, and in particular the p38 pathway, is involved in the control of post-
translational modification of Smads. Specifically, it has been demonstrated that p38 regulates 
the sumoylation of Smad4 by proteins of the PIAS family of E3 ligases, contributing to an 
enhancement of Smad4-dependent transcription (Ohshima & Shimotohno, 2003). 
Together, these results indicate that activation of MAPK pathways may have positive or 
negative regulatory effects on R-Smads, depending on the nature of MAPK activation, which, 
in turn, may affect both the specificity and multiplicity of MAP kinase-dependent 
phosphorylation events. 
 
Nuclear interactions between Smad complexes and MAPK-activated transcription 
factors 
 
Activated R-Smad proteins have been shown to participate in a number of heterogenous 
transcription complexes bound to DNA, as they exhibit a broad capacity to interact with 
numerous transcription factors, such as Sp1. Downstream components of MAP kinase-
signaling pathways, and especially transcription factors of the AP-1 family, may also interact 
with the R-Smad/Smad4 complex in the nucleus, providing an additional level of crosstalk 
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between these pathways (Zhang et al., 1998). c-Jun and JunB, both downstream substrates of 
JNK, are components of the AP-1 complex that are transcriptionally regulated by the TGF-
/Smad pathway (Jonk et al., 1998; Mauviel et al., 1996; Wong et al., 1999), and contribute to 
an autocrine regulatory loop of Smad activity (Verrecchia et al., 2001a). Interestingly, 
transcriptional cooperation depends on the structure of the target promoters, as Smad and AP-
1 cooperate to activate AP-1-dependent promoters, while they tend to antagonize each other 
with regard to Smad-specific transcription dependent on Smad-binding site (Verrecchia et al., 
2001b). While Fos/Jun-Smad3/4 physical interactions may participate in a hetero-tetrameric 
complex bound to AP-1 elements or their adjacent nucleotides on DNA (Zhang et al., 1998), 
data from our own laboratory indicate that both c-Jun and JunB are capable of interrupting 
Smad3-mediated transcription, as Jun/SMAD3 complexes may form off-DNA, preventing 
Smad3 binding to cognate DNA sequences (Verrecchia et al., 2000). We also showed that 
JNK activity promotes such off-DNA association of Jun proteins with Smad3 (Verrecchia et 
al., 2003). Accordingly, in JNK1
-/-
-JNK2
-/-
 (JNK
-/-
) fibroblasts, TNF- had no effect on TGF-
-driven, Smad-dependent, gene transactivation unless jnk1 was introduced exogenously. 
Aside from preventing Smad3 from binding to its cognate DNA binding sites, the JNK 
pathway may also regulate Smad2/3-dependent transcription via alternate mechanisms, for 
example by facilitating c-Jun association with transcriptional co-partners, such as the co-
activators p300/CBP, or the co-repressors c-Ski and TGIF: c-Jun association with CBP/p300 
has been shown to interrupt Smad3-driven transcription by squelching of p300/CBP away 
from Smad complexes ; also c-Jun may physically associate with c-Ski and TGIF and allow 
the latter to exert their repressory activity by interfering with the assembly of Smad2/p300 
complexes (Pessah et al., 2002; Pessah et al., 2001). 
It is interesting to note that the JNK/Jun axis is instrumental to the HTLV-1 Tax oncoprotein 
in repressing TGF- signaling, a mechanisms that may contribute to leukemogenesis (Arnulf 
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et al., 2002). Also, the JNK pathway may contribute to regulate autocrine TGF-1 expression, 
as JNK-deficint fibroblasts constitutively express TGF-1, expression that can be repressed 
by complementation of the cells with JNK (Ventura et al., 2004). 
ATF-2, a downstream substrate of both JNK and p38 MAPKs participates in certain AP-1 
complexes. Its expression is induced by TGF- and transcriptionally regulated by both Smad- 
and TAK1-dependent mechanisms (Hanafusa et al., 1999; Sano et al., 1999). Furthermore, it 
is also possible that AFT-2 participates in transcription complexes in association with Smad 
proteins (Sano et al., 1999). 
Although these are just a few examples of the intricacy of transcriptional control by AP-1 and 
Smad complexes, they suggest a very complex level of integration of the signaling pathways 
resulting in activation of AP-1 via a MAPKs with Smad-driven signals originating from the 
TGF- receptors, leading to either amplification or negative feedback loops controlling TGF-
 effects. Naturally, the outcome of these interactions is further diversified by the presence 
and nature of distinct regulatory sequences within target gene regulatory sequences.  
 
Relevance of the MAPK-Smad interactions to carcinogenesis 
 
TGF- plays a dual role during tumorigenesis. In early stage of carcinogenesis this cytokine 
displays tumor suppressor activities characterized by its antiproliferative activity, its ability to 
induce apoptosis and to promote genomic stability, while in advanced stages of tumor 
development, TGF- acts as a promoter of tumor and metastasis, stimulating the epithelial to 
mesenchymal transition (EMT), matrix metalloproteinase (MMP) expression and 
angiogenesis, and inhibiting immunosurveillance (reviewed in (Akhurst & Balmain, 1999; de 
Caestecker et al., 2000; Derynck et al., 2001; Gold, 1999; Siegel & Massague, 2003). There is 
a particularly complicated and intimate interrelationship between the TGF- system and 
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Ras/MAPK pathways in tumorigenesis.  
Responses that are directly proportional to the level of Smad activity in the nucleus may be 
attenuated by the opposing effects of Ras signaling, as is the case with the antiproliferative 
response to TGF- in epithelial cells (Calonge & Massagué, 1999; Oft et al., 1998; Oft et al., 
1996). Ras-Smad antagonism may for example occur at the level of Smad nuclear 
accumulation (Kretzschmar et al., 1999), but other mechanisms such as opposite regulation of 
cyclin-dependent kinases (Cdks) during the G1 phase of the division cycle may also 
contribute to attenutate TGF- tumor suppressive activities (Hannon & Beach, 1994; 
Reynisdottir et al., 1995). 
Nevertheless, recent data suggest that aberrant activation of MAPK pathways may play an 
important role in diverting the TGF- response towards a pro-oncogenic outcome, and that 
TGF- and activated Ras may cooperate to promote invasive, metastatic disease. For 
example, in the presence of oncogenic Ha-Ras or Ki-Ras, the growth-inhibitory response of 
human prostate and colon cancer cells to TGF- is converted to a Smad-independent 
mitogenic response. In kidney epithelial cells, activation of Raf confers protection against 
TGF--induced apoptosis while enhancing its proinvasive effects (Lehmann et al., 2000), and 
induction of EMT in breast tumor cells is dependent on the presence both of activated Ras and 
of a functional TGF- autocrine loop that is enhanced by Ras (Lehmann et al., 2000; Xie et 
al., 2004). Gene arrays data obtained from human keratinocytes induced by TGF- to undergo 
EMT has provided the first insights into ERK-dependent gene targets with roles in cell–
matrix interactions and cell motility (Xie et al., 2003). 
The interaction between TGF- and Ras signaling can also be cooperative, resulting in 
outcomes that neither pathway would achieve on its own. In fact, several studies indicate that 
aberrant activation of MAPKs may divert the “normal“ TGF- cytostatic response toward a 
pro-oncogenic outcome. Oncogenic Ras in mammary epithelial cells not only attenuates 
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Smad-mediated antiproliferative responses but also endows these cells with the ability to 
respond to TGF- with transdifferentiation into a highly invasive and metastatic phenotype 
(Oft et al., 1998). Breast cancer cells with a hyperactive Ras pathway (owing to EGF receptor 
gene amplification) respond to TGF- with an increased ability to metastasize to bone ((Yin 
et al., 1999), see details below). Thus, the activity of oncogenic Ras with regard to TGF- 
signaling does not simply consist in blocking Smad signaling, but to reprogram epithelial cell 
response to TGF-.  
Induction of epithelial-mesenchymal transition (EMT), which marks the acquisition of an 
aggressive phenotype in certain cancers, has been shown to require cooperation between 
Ras/MAPK and TGF-/Smad cascades (Derynck et al., 2001). In studies designed to identify 
the mechanisms underlying EMT, it has been shown that treatment of Ha-Ras-transformed 
mouse mammary epithelial cells, EpRas, with TGF- results in loss of expression of E-
cadherin, and this effect of TGF- is blocked by inhibition of Ras activity (Janda et al., 2002; 
Oft et al., 2002). Also, by means of mutations in TRI that selectively disable Smad binding 
and activation but not signaling through the MAPK pathways, it has been shown that both 
Smad and MAPK signaling are required for EMT (Itoh et al., 2003; Yu et al., 2002).  
 
TGF--regulated apoptosis is cell type and context dependent. Indeed TGF- provides signals 
for both cell survival and apoptosis (Sanchez-Capelo, 2005; Siegel & Massague, 2003). 
Activation of p38 and JNK MAPK contributes in the TGF- induced apoptosis in numerous 
cell types, such as in prostate cancer cells, murine myeloid cell line M1 and the human 
hepatoma cell line Hep3B (Edlund et al., 2003; Sanchez-Capelo, 2005). It has been proposed 
that delayed p38 activation by TGF-, rather than rapid Smad-independent p38 activation, 
participates in the induction of apoptosis by TGF-, as seen in AML12 murine hepatocytes 
(Yoo et al., 2003). Nevertheless, TGF- can also rescue several cell type from serum 
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withdrawal –induced apoptosis. In the latter case, activation of c-Jun may contribute to this 
rescue (Sanchez-Capelo, 2005). 
 
In numerous tumors, acquisition of matrix metalloproteinase (MMP) activity is associated 
with increased migration and invasiveness of cancer cells. Studies have shown an 
involvement of p38 kinase activity in TGF- induced several MMP biosynthesis in 
fibroblasts, breast epithelial cells or in transformed keratinocytes (Johansson et al., 2000; Kim 
et al., 2004; Kim et al., 2005; Ravanti et al., 1999). 
Recent studies suggest that TGF- plays a specific role in directing metastatic cells to 
particular organ sites such as bone, which is a common site of metastatic foci of breast and 
prostate cancer, a phenomenon that may require cooperation of Smad and MAPKs. Elegant in 
vivo studies by Guise and collaborators, using a breast cancer cell line that metastasizes to the 
bone, demonstrated that expression of a constitutively active TGF- type I receptor enhances 
the expression of PTH-related protein (PTHrP) by tumor cells. PTHrP in turn recruits bone-
resorbing osteoclasts, thus increasing osteolytic bone metastases, and decreasing survival. On 
the other hand, expression of a dominant negative TGF- type II receptor had the opposite 
effects, reducing tumor metastases (Yin et al., 1999). The authors further identified that both 
TGF-/Smad and p38 signaling pathways cooperate to induce the expression of PTHrP and 
promote metastasis of breast cancer cells to bone (Kakonen et al., 2002). Together these data 
point to tumor cell autonomous oncogenic effects of TGF- and its gene targets on 
metastases.  
MAP kinase activation can also contribute to the TGF- metastasis promotion by stimulating 
migration of tumor cells (Dumont et al., 2003). Furthermore, it has been shown that 
expression of a mutant TGF- type I receptor unable to bind R-Smad but maintaining kinase 
activity enhances tumorigenesis but suppresses metastasis of MCF10A-derived cell lines 
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(Tian et al., 2004; Tian et al., 2003). Clearly emphasizing the bifunctional role of TGF- in 
carcinogenesis. 
 
Conclusions 
 
Although experimental carcinogenesis has proven that targeting TGF- is likely to be 
interesting to treat human malignant tumors, much remains to be understood before one can 
precisely unravel the bi-functional tumor suppressor/pro-oncogenic role of TGF-, and 
propose adequate therapeutic options aimed at interfering with TGF- signals. The fine line 
drawn between mechanisms involving TGF- signaling that are either deleterious or 
beneficial in the context of tumor progression (cell-type specificity, organ context, degree of 
progression of tumor before treatment, etc) and the complexity of the interactions with other 
signaling cascades make it extremely difficult to identify the proper context in which 
inhibition of TGF- signaling will be really advantageous to the patient, i.e. restore TGF- 
tumor suppressive functions.  
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Legends to figures 
 
Figure 1 
MAPK network 
Transduction of the signal from the plasma membrane to the nucleus occurs through the 
sequential activation of MAPKKKs, MAPKKs, MAPKs and their direct nuclear targets, 
kinases (italics) and transcription factors. For further details, refer to the corresponding text 
within the manuscript. 
 
 
Figure 2 
Activation of Smad and MAP kinases by TGF- and their interactions  
Upon TGF- ligation toTRII, the latter phosphorylates and activates TRI, which in turn 
phosphorylates the R-Smads, Smad2/3. Activated R-Smads bind Smad4 and translocate to the 
nucleus to act as transcription factors, controlled by a balance between transcriptional co-
activators (co-A) or co-repressors (co-R). The three principal MAPKs can be activated by 
TGF- in Smad-dependent or -independent ways (see text for further details). MAPKs, 
following activation by TGF- or others stimuli such as growth factors or pro-inflammatory 
cytokines, can regulate Smad activation by a direct phosphorylation or through their 
downstream effector molecules. An example is shown, whereby activated Jun and ATF-2 
modulate Smad transcriptional activity through direct physical contacts or by altering the 
balance between transcriptional co-activators or co-repressors.     : phosphorylation.  
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